Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implicationsmarketing2021-02-11T23:40:44+00:00October 15th, 2019|2019 Publications, Publications| 更多详细信息
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomamarketing2021-02-11T23:43:09+00:00October 1st, 2019|2019 Publications, Publications| 更多详细信息
NOW AVAILABLE! MRD solutions for B- and T-cell clonality trackingmarketing2019-09-23T22:05:58+00:00August 26th, 2019|Product Releases| 更多详细信息
日本MHLW批准Invivoscribe公司的LeukoStrat CDx FLT3突变试剂盒作为第一三共制药公司的Quizartinib的伴随诊断，用于复发/难治性FLT3-ITD AML的治疗。 扩展使用包括收集在EDTA的样本marketing2022-01-03T02:51:50+00:00June 19th, 2019|2019 Press Releases, Press Releases| 更多详细信息
Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myelomamarketing2021-02-15T20:01:10+00:00June 6th, 2019|2019 Publications, Publications| 更多详细信息
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesmarketing2021-02-26T19:10:45+00:00May 21st, 2019|2019 Press Releases, Press Releases| 更多详细信息
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasmsmarketing2021-02-11T23:46:14+00:00March 21st, 2019|2019 Publications, Featured Publications, Publications| 更多详细信息
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|2018 Press Releases, Press Releases| 更多详细信息
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japanmarketing2021-02-26T19:11:48+00:00November 19th, 2018|2018 Press Releases, Press Releases| 更多详细信息
